When does the Medicare GLP-1 Bridge program end?

The Bridge is currently scheduled to run through December 31, 2027. It launched July 1, 2026. CMS has not announced what happens after the end date — the program could be extended, made permanent, replaced by another payment model, or allowed to expire.

Will the GLP-1 Bridge be renewed or made permanent?

Nobody knows yet. Renewal will likely depend on the program's cost to Medicare, evidence of health benefits among participants, drug price trends (including generic competition), and political priorities in Washington. CMS typically announces decisions about expiring programs months in advance — watch CMS.gov announcements in 2027.

What would GLP-1 drugs cost if the Bridge ends without a replacement?

If coverage reverted to pre-Bridge rules, Part D would again exclude GLP-1s prescribed for weight loss alone. List prices exceed $1,000 a month, though manufacturer self-pay programs have offered lower cash prices, and generic semaglutide entering the market is expected to push prices down substantially. Beneficiaries with type 2 diabetes or a qualifying cardiovascular indication would still have a Part D coverage pathway.

Should I wait to enroll in the Bridge since it might end?

Waiting generally works against you. Benefits accrue while you are on the medication, and every month you delay is a month at the $50 copay you don't get back. There is no penalty for participating in a program that later ends — you would simply transition to whatever coverage options exist at that time.

What Happens When the Medicare GLP-1 Bridge Ends in 2027?

The $50-a-month program has an expiration date: December 31, 2027. Here's what could happen after that, what your options would be in each scenario, and why the smart move today is almost certainly not to wait on the sidelines.

By Alex Carter, Medicare benefits specialist · Published July 6, 2026 · Reviewed July 6, 2026

The Medicare GLP-1 Bridge launched on July 1, 2026, and by design it is temporary: the program is scheduled to run through December 31, 2027. That's an 18-month window in which eligible beneficiaries can get Wegovy, Zepbound, and other covered GLP-1 medications for a flat $50 monthly copay.

For a medication that generally must be continued long-term to maintain its benefits, an end date raises an obvious and uncomfortable question: what happens to the millions of people on these drugs when the program stops? Honest answer up front: nobody knows yet — including CMS. But the possible paths are knowable, and so is the smart way to prepare. This article maps both.

Why does the Bridge have an end date at all?

The Bridge is structured as a time-limited program, not a permanent change to the Part D benefit. That structure lets Medicare test a big question at manageable risk: what does it cost — and what health benefits does it produce — to cover weight-loss GLP-1s for the roughly 3.8 million beneficiaries who qualify?

The economics only became feasible recently. Under the program, Medicare pays manufacturers a negotiated net price of roughly $245 per month — a fraction of list prices that exceed $1,000 — with participants contributing $50 of that. The 18-month window gives CMS real-world data on uptake, spending, and outcomes before anyone commits taxpayers to a permanent benefit.

In other words: the end date isn't a bug or a hidden trapdoor. It's the whole point of a pilot. What comes after depends on what the data shows — and on decisions that haven't been made yet.

Sources: CMS.gov — Medicare GLP-1 Bridge program; KFF — estimates of the Bridge-eligible population.

The four scenarios after December 31, 2027

Broadly, there are four ways this can go. We've ordered them from most reassuring to least:

The program is extended or made permanent. If participation is strong and costs land near projections, extending the Bridge — or folding weight-loss GLP-1 coverage into the regular Part D benefit — becomes the path of least disruption. Precedent exists: Medicare pilots that work often get renewed or absorbed into the standard program.
A successor model takes over. CMS already has a related payment model on paper: BALANCE (2026–2031), which was slated to bring negotiated GLP-1 pricing into Part D before its Part D component was postponed in April 2026. A post-Bridge world could revive BALANCE or something like it — coverage would continue, though copays and rules could differ from today's flat $50.
Coverage narrows. A budget-driven middle path: the program continues but with tighter eligibility (for example, only the highest-BMI door), higher copays, or step-therapy requirements. You'd keep a pathway, but with more friction.
The program simply expires. Part D reverts to pre-Bridge rules, under which weight-loss-only GLP-1 prescriptions are excluded from coverage. This is the scenario the rest of this article prepares you for — and even here, the 2028 landscape looks very different from the 2025 one.

Watch the calendar, not the rumor mill. CMS typically announces the fate of expiring programs months ahead, and any changes to 2028 Part D coverage would surface during the October–December 2027 open enrollment season at the latest. Decisions will be posted on CMS.gov — not broken on social media.

If it expires: what your options would look like in 2028

Suppose the worst case happens and the Bridge ends with no successor. Your options would depend heavily on why you take the drug:

You have type 2 diabetes. Nothing changes. GLP-1s prescribed for diabetes (Ozempic, Mounjaro) are covered under regular Part D with prior authorization, Bridge or no Bridge — and those copays count toward the $2,100 annual cap.
You have established cardiovascular disease. Wegovy's FDA-approved indication for reducing heart attack and stroke risk gives you a separate, permanent Part D coverage pathway. Our cardiovascular coverage guide explains the criteria.
You take it for weight loss alone. This is the group the expiration would hit. The realistic fallbacks: manufacturer self-pay programs, which have offered cash prices well below list; generic semaglutide, which is expected to reach the market as patents expire and should push prices down substantially (see our generics tracker); and for some, Medicaid coverage depending on the state (see options outside Medicare).

One more reason 2028 won't look like 2025: by then, the market will have more competitors — including oral GLP-1s and the drugs now in late-stage development on our pipeline tracker — and competition has historically been the strongest force pushing drug prices down.

Pricing and coverage details above are illustrative and change frequently — verify current options with your plan, pharmacy, and FDA.gov.

What to do now: four moves that make sense in every scenario

1. Don't wait on the sidelines

If you qualify, delaying enrollment out of fear the program ends is paying full risk for no benefit. Every month on the Bridge is health benefit gained at $50 — and there's no penalty or clawback if the program later expires. Check your eligibility.

2. Have the "exit plan" talk with your doctor

Ask two questions now: "If I lose coverage in 2028, what's our plan — taper, switch, or self-pay?" and "Could I qualify under a diabetes or cardiovascular indication?" A documented diagnosis today can become a coverage pathway tomorrow.

3. Bank the difference

If your pre-Bridge budget assumed several hundred dollars a month for this medication, consider setting aside part of the savings. A cushion of even $1,000–$2,000 buys months of transition time in the worst-case scenario.

4. Mark October 2027

Medicare open enrollment (Oct 15 – Dec 7, 2027) is when 2028 coverage becomes concrete. Whatever CMS decides, that's your window to compare plans and act. Check CMS.gov announcements — not headlines — for the official word.

Make the most of the window that's open now

The Bridge is live today. Find out in about a minute whether you qualify for the $50 copay.

Check my eligibility →